JLB2-110c

CC(N[C@H](C(N[C@H](C(N[C@H](C(NCCCC[C@@H]1NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H]2CCCN2C([C@H]3CCCN3C1=O)=O)=O)CC4=CNC=N4)=O)CC5=CC=CC=C5)=O)CCCNC(N)=N)=O)CC6=CNC7=C6C=CC=C7)=O)CN)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O

[1]Ericson MD, et al. Incorporation of Three Extracyclic Arginine Residues into a Melanocortin Macrocyclic Agonist (c[Pro-His-DPhe-Arg-Trp-Dap-Lys (Arg-Arg-Arg-Ac) -DPro]) Decreases Food Intake When Administered Intrathecally or Subcutaneously Compared to a Macrocyclic Ligand Lacking Extracyclic Arginine Residues (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro) ]. ACS Pharmacol Transl Sci. 2024 Apr 2;7 (4) :1114-1125.